Drug & intervention
lazertinib
RxCUI 2691150
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
24 shownA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202 · 2026-07-28
RECRUITINGA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16
RECRUITINGLazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentNCT06106802 · 2024-06-11
RECRUITINGA Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerNCT06156527 · 2023-09-05
RECRUITINGA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · 2022-11-11
RECRUITINGEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16
ACTIVE_NOT_RECRUITINGLazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNCT06020989 · 2023-09-01
UNKNOWNAmivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsNCT05299125 · 2023-05-24
COMPLETEDPremedication to Reduce Amivantamab Associated Infusion Related ReactionsNCT05663866 · 2023-05-18
ACTIVE_NOT_RECRUITINGAmivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKINCT05601973 · 2023-03-27
ACTIVE_NOT_RECRUITINGLazertinib 160mg in EGFR T790M NSCLCNCT05701384 · 2023-02-01
UNKNOWNImpact of Lazertinib Dose Modification on Effectiveness and SafetyNCT05716672 · 2023-02-01
UNKNOWNA Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05
ACTIVE_NOT_RECRUITINGLazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesNCT05477615 · 2022-08-01
UNKNOWNLazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerNCT05377788 · 2022-07-31
UNKNOWNA Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyNCT05338619 · 2022-06-30
UNKNOWNNeoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerNCT06268210 · 2022-02-07
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureNCT04988295 · 2021-11-17
ACTIVE_NOT_RECRUITINGA Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)NCT04965090 · 2021-09-30
COMPLETEDA Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30
ACTIVE_NOT_RECRUITINGA Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04075396 · 2019-10-16
COMPLETEDA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerNCT04077463 · 2019-09-04
ACTIVE_NOT_RECRUITINGStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerNCT02609776 · 2016-05-24
ACTIVE_NOT_RECRUITINGRetrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCNCT05862194 · 2015-06-01
COMPLETEDConditions being studied
Carcinoma, Non-small-Cell Lung9Non-small Cell Lung Cancer4EGFR T790M2Non Small Cell Lung Cancer2Advanced or Metastatic Non-small Cell Lung Cancer1EGFR Positive Non-small Cell Lung Cancer1Lazertinib1Lung Cancer Stage IV1Metastatic Lung Non-Small Cell Carcinoma1Metastatic Non Small Cell Lung Cancer1Metastatic Non-small Cell Lung Cancers1Non-Small Cell Lung Cancer Metastatic1Non-small Cell Lung Cancer Stage III1Non-Small-Cell Lung Cancer1Non-squamous Non-small-cell Lung Cancer1Recurrent Non Small Cell Lung Cancer1
Research locations
Leading sponsors
Janssen Research & Development, LLC11Samsung Medical Center2Yonsei University2ETOP IBCSG Partners Foundation1Jin Hyoung Kang1Latin American Cooperative Oncology Group1Memorial Sloan Kettering Cancer Center1National Cancer Center, Korea1Pusan National University Hospital1Sehhoon Park1Sung Yong Lee1Yuhan Corporation1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.